Loading clinical trials...
Loading clinical trials...
CP-675,206 (tremelimumab) is a fully humanized monoclonal antibody that binds to activated T lymphocytes and by enhancing their activation may produce a stimulation of the immune response against tumo...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Clinica Universidad de Navarra, Universidad de Navarra
Collaborators
NCT07175441 · Advanced Unresectable Hepatocellular Carcinoma
NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more
NCT06427941 · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, and more
NCT05842174 · Hepatocellular Carcinoma
NCT07164313 · Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, and more
Hospital Universitario Reina Sofía
Córdoba
Hospital Universitario 12 de Octubre
Madrid
Clinica Universitaria de Navarra
Pamplona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions